SCHEMBL9102296

SCHEMBL9102296

CCCC(CN1CC(O)C1)N(C)C(=O)c1ccc(F)c(C)c1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ OPRK1 P41145 4/20 0.36
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ MAOA P21397 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ HTR7 P34969 2/20 0.33
▸ OPRM1 P35372 1/20 0.33
▸ OPRD1 P41143 1/20 0.33
▸ MAPK14 Q16539 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ SLC6A4 P31645 1/20 0.33
▸ ADRA1A P35348 2/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ DRD4 P21917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9102284 1.00 OPRK1 (0.36) OPRK1MEN1KMT2AL3MBTL1MAOA
SCHEMBL9106299 0.92 OPRK1 (0.35) OPRK1MEN1KMT2AL3MBTL1MAOA
SCHEMBL9105601 0.92 OPRK1 (0.35) OPRK1MEN1KMT2AL3MBTL1MAOA
SCHEMBL31478912 0.91 OPRK1 (0.37) OPRK1MEN1KMT2AHRH3OPRM1
SCHEMBL9104979 0.91 OPRK1 (0.37) OPRK1MEN1KMT2AHRH3OPRM1
SCHEMBL9105962 0.91 OPRK1 (0.37) OPRK1MEN1KMT2AHRH3OPRM1
SCHEMBL9101033 0.90 TAS1R3 (0.41) OPRK1KMT2AHRH3OPRM1OPRD1
SCHEMBL9102337 0.90 TAS1R3 (0.41) OPRK1KMT2AHRH3OPRM1OPRD1
SCHEMBL31478849 0.88 OPRK1 (0.43) OPRK1MAOAMAOBSLC6A4
SCHEMBL9100354 0.88 OPRK1 (0.43) OPRK1MAOAMAOBSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8361998-B2 Compounds and their use as IKACh blockers ASTRAZENECA AB 2013-01-29 — — US claimed
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2012-06-07 — — US claimed
WO-2025082731-A1 INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA MOSANNA THERAPEUTICS AG (CH) 2025-04-24 — — WO disclosed
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2013-06-06 — — US disclosed
US-8361998-B2 Compounds and their use as IKACh blockers ASTRAZENECA AB 2013-01-29 — — US disclosed
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS ASTRAZENECA AB (SE) 2012-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143858-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 OPRK1 398/4885MEN1 482/4885KMT2A 552/4885
US-20120142659-A1 COMPOUNDS AND THEIR USE AS IKACH BLOCKERS KCNH2, KCNJ2, KCNH3 OPRK1 398/4885MEN1 482/4885KMT2A 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback